Hidden Costs for Patients Starting a Specialty Drug Regimen

Marc O'Connor, COO and chief strategy officer at Curant Health, discusses the out-of-pocket costs that can emerge for patients starting a specialty medication regimen.

Marc O'Connor, COO and chief strategy officer at Curant Health, discusses the out-of-pocket costs that can emerge for patients starting a specialty medication regimen.

Related Videos
Senior Male Research Scientist is Using a Tablet Computer in a Modern High-Tech Laboratory. Genetics and Pharmaceutical Studies and Researches | Image Credit: Gorodenkoff - stock.adobe.com
Acute psoriasis on the elbows is an autoimmune incurable dermatological skin disease. Large red, inflamed, flaky rash on the knees. Joints affected by psoriatic arthritis | Image Credit: SNAB - stock.adobe.com
Portrait of a smiling female pharmacist, male colleague working with drugs in the background. | Image Credit: bnenin - stock.adobe.com
Dermatologist examining the skin of a patient | Image Credit: thodonal - stock.adobe.com
Patient with cancer receiving an infusion | Image credit: RFBSIP - stock.adobe.com
Stack of files and gavel | Image credit: BillionPhotos.com - stock.adobe.com
Public Health Matters podcast logo
Cancer patient with IV | Image credit: Monkey Business - stock.adobe.com
Capitol Building | Image credit: lazyllama - stock.adobe.com
Related Content

FDA Grants Full Approval to Merck’s Keytruda for MSI-H/dMMR Solid Tumors

March 31st 2023

Pharmacy Focus: Psychedelic Pharmacy - Understanding Natural vs. Synthetic Psychedelics

January 13th 2023

Three Key Services Pharmaceutical Manufacturers Provide Patients: Are You Taking Advantage?

March 30th 2023

Pharmacy Focus: Public Health Matters- Celebrating American Pharmacist Month Part 2 with Autumn Zuckerman

October 13th 2022

AbbVie’s Upadacitinib Meets Primary Endpoint for Systemic Lupus Erythematosus

March 28th 2023

The Rise of Health System Specialty Pharmacy Remote Call Centers: Out of Office…For Good?

March 28th 2023

FDA Grants Full Approval to Merck’s Keytruda for MSI-H/dMMR Solid Tumors

March 31st 2023

Pharmacy Focus: Psychedelic Pharmacy - Understanding Natural vs. Synthetic Psychedelics

January 13th 2023

Three Key Services Pharmaceutical Manufacturers Provide Patients: Are You Taking Advantage?

March 30th 2023

Pharmacy Focus: Public Health Matters- Celebrating American Pharmacist Month Part 2 with Autumn Zuckerman

October 13th 2022

AbbVie’s Upadacitinib Meets Primary Endpoint for Systemic Lupus Erythematosus

March 28th 2023

The Rise of Health System Specialty Pharmacy Remote Call Centers: Out of Office…For Good?

March 28th 2023

FDA Grants Full Approval to Merck’s Keytruda for MSI-H/dMMR Solid Tumors

March 31st 2023

Pharmacy Focus: Psychedelic Pharmacy - Understanding Natural vs. Synthetic Psychedelics

January 13th 2023

Three Key Services Pharmaceutical Manufacturers Provide Patients: Are You Taking Advantage?

March 30th 2023

Pharmacy Focus: Public Health Matters- Celebrating American Pharmacist Month Part 2 with Autumn Zuckerman

October 13th 2022

AbbVie’s Upadacitinib Meets Primary Endpoint for Systemic Lupus Erythematosus

March 28th 2023

The Rise of Health System Specialty Pharmacy Remote Call Centers: Out of Office…For Good?

March 28th 2023
© 2023 MJH Life Sciences

All rights reserved.